Trial Profile

A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ONCT 216 (Primary) ; Vincristine (Primary)
Indications Ewing's sarcoma
Focus Adverse reactions; First in man
Sponsors Oncternal Therapeutics, Inc.; Tokalas, Inc.

Most Recent Events

12 Sep 2024 According to a Oncternal Therapeutics media release, results from this trial were recently published (Myers 2024).
21 Jun 2022 Status changed from active, no longer recruiting to discontinued.
19 Apr 2022 Status changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com